Hubei Goto Biopharm Co.,Ltd. (300966.SZ)
CNY 17.5
(-0.91%)
CNY 17.5
(-0.91%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 785.72 Million CNY | 2.0% |
| 2022 | 770.3 Million CNY | 376.84% |
| 2021 | 161.54 Million CNY | 15.58% |
| 2020 | 139.76 Million CNY | -5.13% |
| 2019 | 147.32 Million CNY | 82.11% |
| 2018 | 80.89 Million CNY | 44.59% |
| 2017 | 55.95 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.19 Billion CNY | 42.42% |
| 2024 Q3 | 994.68 Million CNY | -16.95% |
| 2024 Q1 | 840.96 Million CNY | 7.03% |
| 2023 Q3 | 759.64 Million CNY | 1.63% |
| 2023 FY | 785.72 Million CNY | 2.0% |
| 2023 Q4 | 785.72 Million CNY | 3.43% |
| 2023 Q2 | 747.44 Million CNY | -4.73% |
| 2023 Q1 | 784.51 Million CNY | 1.85% |
| 2022 Q3 | 568.22 Million CNY | 3.57% |
| 2022 Q2 | 548.62 Million CNY | 109.99% |
| 2022 Q1 | 261.26 Million CNY | 61.73% |
| 2022 FY | 770.3 Million CNY | 376.84% |
| 2022 Q4 | 770.3 Million CNY | 35.56% |
| 2021 Q4 | 161.54 Million CNY | 13.55% |
| 2021 Q1 | 178.27 Million CNY | 27.56% |
| 2021 FY | 161.54 Million CNY | 15.58% |
| 2021 Q3 | 142.26 Million CNY | -12.52% |
| 2021 Q2 | 162.62 Million CNY | -8.78% |
| 2020 Q1 | - CNY | -100.0% |
| 2020 FY | 139.76 Million CNY | -5.13% |
| 2020 Q4 | 139.76 Million CNY | 0.0% |
| 2020 Q3 | - CNY | -100.0% |
| 2020 Q2 | 157.43 Million CNY | 0.0% |
| 2019 FY | 147.32 Million CNY | 82.11% |
| 2019 Q4 | 147.32 Million CNY | 0.0% |
| 2018 FY | 80.89 Million CNY | 44.59% |
| 2017 FY | 55.95 Million CNY | 0.0% |